The Treatment Action Campaign is calling for the phase out of Stavudine (D4T) as a first line treatment in the public health care sector. On 25th November 2012, TAC General Secretary Vuyiseka Dubula and Dr Eric Goemaere ( MSF) will be debating with the former head of the South African clinicians society why we do not need D4T . The TAC members and patients will hold a demonstration outside the Cape Town International during the D4T debate at the Clinician Society Conference.
D4T was previously one of three antiretroviral drugs (ARVs)...
Today is the trial of Professor Karabus in the UAE.
On 26 September TAC sent a letter to the Minister of International Relations and Cooperation requesting urgent intervention in the case of Professor Cyril Karabus. We have not received a proper reply. Professor Karabus served most of his life as a paediatrician in the South African public health system. He worked for many years at Red Cross Children's Hospital. By all accounts he has dedicated his life to public service. After retiring, he worked as a locum in the United Arab Emirates (UAE). No doubt if Professor Karabus had instead...
Thank you all for coming and welcome to Johannesburg.
We are joined today by over 40 activists from all parts of the world, including organisations of people living with HIV, MSF, as well as individual experts and lawyers who have fought for the rights of people to access affordable quality medicines. In this room is the residue of experience from the many successful battles that changed the landscape of the response to HIV and in doing so has prevented millions of deaths.
Some people will remember the last time we met as a group in South Africa at a seminar...
Last Tuesday, 23 October, MSF and TAC co-hosted a meeting to examine South Africa’s Intellectual Property Policy – currently under development by the Department of Trade and Industry (DTI) - from a public health perspective.
The meeting focused on how amending South Africa’s patent laws to include key flexibilities allowed under for international law could protect health and strengthen manufacture of generic drugs, including by local companies. Local and international experts outlined the current challenges posed by excessive pharmaceutical patenting and the limitations of the...Read more
Treatment Action Campaign has written a letter to the minister of health raising concerns about some specifications in the ARV tender. The inclusion of FDC’s in the tender is welcomed but TAC would like for price to not be the only deciding factor when choosing which regimens to procure. FDC’s have been proven to be beneficial for improved adherence to treatment. FDCs make prescribing, dispensing and monitoring treatment easier for nurses and pharmacists.
TAC urges the Department of Health to intervene in the ARV tender process to ensure that FDCs will be preferred over mono-...Read more